USPTO 2015–2025 USPTO PatentsView Foreign Corporation

KANE Biotech Inc.

USPTO PatentsView assignee record - 7 granted patents across 13 technology areas, active 2017–2023. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

Total patents granted

CPC technology areas

16.3

Avg claims per patent

-25%

5-year filing velocity

The verdict

KANE holds 7 US patents across 13 technology areas, rank #36,057 of 50,000 tracked assignees.

#36,057
of 50,000 US assignees by volume: Top 61%
by Innovation Score (31.9/100): 16.3
avg claims per patent: -25%
filing velocity, last 5 yrs

Portfolio overview

KANE Biotech Inc. has been granted 7 US utility patents between 2017 and 2023, placing KANE Biotech Inc. at rank #36,057 across all assignees tracked by PlainPatent. This portfolio spans 13 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.3 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a Foreign Corporation, KANE Biotech Inc. is one of the more focused assignees in the PatentsView dataset. By volume, KANE sits between K S Paterson Nominees PTY Ltd (7 patents, rank #36,053) and KARL Mayer Textilmaschinenfabrik Gmbh (7 patents, rank #36,061) - the closest US assignees by grant volume. The composite Innovation Score of 31.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 3 grants, compared with 4 in the 2015–2019 window, a -25% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. KANE Biotech Inc.'s 16.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 13 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark KANE Biotech Inc. against peers pursuing similar technology classes.

K S Paterson Nomi…

7
K-motion Interact…

7
K2 Energy Solutio…

7
Kahtoola

7
Kangstem Biotech

7
Kannuu PTY

7
Kansai Chemical E…

7
KARL Mayer Textil…

7
KANE Biotech ◀

7

What this shows KANE holds 7 patents at rank #36,057, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near KANE

By rank, the assignees closest to #36,057 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in KANE's primary technology class.

KANE's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

32 Top 61% higher than 39% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

KANE Biotech Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	14.3%
2018	2	28.6%
2019	1	14.3%
2021	2	28.6%
2023	1	14.3%

Which technologies does KANE Biotech Inc. patent most?

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 6

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 4

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 4

A01N - PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF ; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES ; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS 3

A61Q - SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS 3

A23B - PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES 2

A23V - INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION 2

A61B - DIAGNOSIS; SURGERY; IDENTIFICATION 2

A61C - DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE 2

A61L - METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES 1

C02F - TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE 1

A23L - FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF 1

A01P - BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS 1

Top 13 of 13 technology areas

Patent Moat Analysis

Portfolio Volume Light

Tech Breadth Focused

Claim Depth Standard

Velocity Declining

Where it ranks

Overall rank by patents

#36,057

Across all tracked assignees

Innovation Score

31.9 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does KANE Biotech Inc. hold?

KANE Biotech Inc. holds 7 US granted patents filed between 2017 and 2023, spanning 13 technology areas.

What is KANE Biotech Inc.'s Innovation Score?

KANE Biotech Inc. has an Innovation Score of 31.9 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does KANE Biotech Inc. focus on?

KANE Biotech Inc.'s top technology area is A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES) with 6 patents. The company has filed patents in 13 CPC subclasses total.

Is KANE Biotech Inc.'s patent filing rate increasing or decreasing?

KANE Biotech Inc.'s recent filing velocity is -25% compared to the prior five-year period. Filing activity has slowed relative to earlier years.

What does claim depth mean for KANE Biotech Inc.'s patents?

KANE Biotech Inc.'s patents average 16.3 claims each. This falls within the standard range, providing solid legal coverage.

How is the KANE Biotech Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

KANE's 7 grants land it in the top 61% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - KANE ranks #36,057 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61K - see who else leads that technology area. A61K leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.